Adenosine promotion of cellular migration in bronchial epithelial cells is mediated by the activation of cyclic adenosine monophosphate-dependent protein kinase A

Department of Internal Medicine, Nebraska Medical Center, Omaha, NE 68198-5815, USA.
Journal of Investigative Medicine (Impact Factor: 1.5). 12/2007; 55(7):378-85. DOI: 10.2310/6650.2007.00019
Source: PubMed

ABSTRACT Migration of neighboring cells into the injury is important for rapid repair of damaged airway epithelium. We previously reported that activation of the A(2A )receptors (A(2A)ARs) mediates adenosine-stimulated epithelial wound healing, suggesting a role for adenosine in migration. Because A(2A)AR increases cyclic adenosine monophosphate (cAMP) levels in many cells, we hypothesized that cAMP-dependent protein kinase A (PKA) is involved in adenosine-mediated cellular migration. To test this hypothesis, we stimulated a human bronchial epithelial cell line with adenosine and/or A(2A)AR agonist (5'-(N-cyclopropyl)-carboxamido-adenosine [CPCA]) in the presence or absence of adenosine deaminase inhibitor (erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride [EHNA]). Cells treated with adenosine or CPCA demonstrated a concentration-dependent increase in migration. Similar results were observed in the presence and absence of EHNA. To confirm A(2A) involvement, we pretreated the cells for 1 hour with the A(2A) receptor antagonist ZM241385 and then stimulated them with either adenosine or CPCA. To elucidate PKA's role, cells were pretreated for 1 hour with either a PKA inhibitor (KT5720) or a cAMP antagonist analogue (Rp-cAMPS) and then stimulated with adenosine and/or CPCA. Pretreatment with KT5720 or Rp-cAMPS resulted in a significant decrease in adenosine-mediated cellular migration. PKA activity confirmed that bronchial epithelial migration requires cAMP and PKA activity. When cells were wounded and stimulated with CPCA, an increase in PKA activity occurred. Pretreatment for 1 hour with either KT5720 or Rp-cAMPS resulted in a significant decrease in adenosine-mediated PKA activation. These data suggest that adenosine activation of A(2A)AR augments epithelial repair by increasing airway cellular migration by PKA-dependent mechanisms.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a neutrophilic inflammatory disorder that is weakly responsive to glucocorticoids. Identification of ways to enhance the anti-inflammatory activity of glucocorticoids is, therefore, a major research objective. Adenosine receptor agonists that target the A2B-receptor-subtype are efficacious in several cell-based assays and pre-clinical models of inflammation. Accordingly, the present study was designed to determine if a selective A2B-receptor agonist, Bay 60-6583, and a glucocorticoid, dexamethasone in combination display putative anti-inflammatory activity that is superior to either drug alone. In BEAS-2B human airway epithelial cells stably transfected with CRE and GRE reporter constructs, Bay 60-6583 promoted CRE-dependent transcription and enhanced GRE-dependent transcription by adenosine A2B-receptor-mediated mechanism that was associated with cAMP formation and abolished by an inhibitor of cAMP-dependent protein kinase. Analysis of the concentration-response relationship that described the enhancement of GRE-dependent transcription showed that Bay 60-6583 increased the magnitude of response without affecting the potency of dexamethasone. Bay 60-6583 and dexamethasone also induced a panel of genes that, collectively, could have benefit in COPD. These were categorised into genes that were induced in a positive cooperative manner (RGS2, p57kip2), an additive manner (TTP, BRL-1) or by Bay 60-6583 (CD200, CRISPLD2, SOCS3) or dexamethasone (GILZ) only. Thus, the gene induction "fingerprints" produced by Bay 60-6583 and dexamethasone, alone and in combination, were distinct. Collectively, through their actions on gene expression, an adenosine A2B-receptor agonist and a glucocorticoid administered together may have utility in the treatment of inflammatory disorders that respond sub-optimally to glucocorticoids as a monotherapy.
    Journal of Pharmacology and Experimental Therapeutics 07/2013; 346(3). DOI:10.1124/jpet.113.206284 · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung injury caused by inhalation of dust from swine concentrated animal feeding operations (CAFO) involves the release of inflammatory cytokine interleukin 8 (IL-8), which is mediated by protein kinase C epsilon (PKCε) in airway epithelial cells. Once activated by CAFO dust, PKCε is responsible for slowing cilia beating and reducing cell migration for wound repair. Conversely, the cAMP-dependent protein kinase (PKA) stimulates contrasting effects, such as increased cilia beating and an acceleration of cell migration for wound repair. We hypothesized that a bidirectional mechanism involving PKA and PKC regulates epithelial airway inflammatory responses. To test this hypothesis, primary human bronchial epithelial cells and BEAS-2B cells were treated with hog dust extract (HDE) in the presence or absence of cAMP. PKCε activity was significantly reduced in cells that were pre-treated for one hour with 8-Br-cAMP before exposure to HDE (p<0.05). HDE-induced IL-6 and IL-8 release was significantly lower in cells that were pre-treated with 8-Br-cAMP (p<0.05). To exclude exchange protein activated by cAMP (EPAC) involvement, cells were pre-treated with either 8-Br-cAMP or 8CPT-2Me-cAMP (EPAC agonist). 8CPT-2Me-cAMP did not activate PKA and did not reduce HDE-stimulated IL-6 release. In contrast, 8-Br-cAMP decreased HDE-stimulated TNFα converting enzyme (TACE; ADAM-17) activity and subsequent TNFα release (p <0.001). 8-Br-cAMP also blocked HDE-stimulated IL-6 and keratinocyte-derived chemokine (KC) release in precision-cut mouse lung slices (p<0.05). These data show bidirectional regulation of PKCε via a PKA-mediated inhibition of TACE activity resulting in reduced PKCε-mediated release of IL-6 and IL-8.
    AJP Lung Cellular and Molecular Physiology 08/2014; 307(8). DOI:10.1152/ajplung.00373.2013 · 4.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenosine levels are elevated in the lungs of patients with asthma and chronic obstructive pulmonary disease (COPD), where it balances between tissue repair and excessive airway remodeling. We previously demonstrated activation of adenosine A2A receptor promotes epithelial wound closure. However, the mechanism by which adenosine-mediated wound healing occurs after cigarette smoke exposure has not been investigated. The current study investigates if cigarette smoke exposure alters adenosine-mediated reparative properties via its ability to induce a shift in the oxidant/antioxidant balance. Utilizing an in vitro wounding model, bronchial epithelial cells were exposed to 5% cigarette smoke extract (smoke extract), wounded and stimulated with either 10 μM adenosine or the specific A2A receptor agonist, 5'-(N-Cyclopropyl)-carboxamido-adenosine (CPCA; 10 μM) and assessed for wound closure. In a subset of experiments, bronchial epithelial cells were infected with adenovirus vectors encoding human superoxide dismutase and/or catalase or control vector. In the presence of 5% smoke extract, there was significant delay in both adenosine- and CPCA-mediated wound closure. However, cells pretreated with N-acetylcysteine (NAC), a non-specific antioxidant, reversed smoke extract-mediated inhibition. We found cells overexpressing mitochondrial catalase repealed smoke extract inhibition of CPCA-stimulated wound closure while superoxide dismutase overexpression had no effect. Kinase studies revealed smoke extract significantly reduced A2A-mediated activation of cAMP-dependent protein kinase (PKA); however, pretreatment with NAC reversed this effect. In conclusion, our data suggest that cigarette smoke exposure impairs A2A-stimulated wound repair via a reactive oxygen species-dependent mechanism and provides a better understanding of adenosine signaling that may direct the development of pharmacological tools for treatment of chronic inflammatory lung disorders.
    American Journal of Respiratory Cell and Molecular Biology 01/2013; DOI:10.1165/rcmb.2011-0273OC · 4.11 Impact Factor